Industry Reports

Leading provider of clinical trial support services, Paragon International affirmed new name "Paragon Global CRS" The name symbolizes the variety of services currently being offered by…
Read More...

Spectris plc acquires Concept Life Sciences, the integrated drug discovery, development and analytical services and environmental consultancy company. Spectris has acquired the Concept…
Read More...

Clinical-stage, biotherapeutics company, SillaJen committed to the development of oncolytic immunotherapy products for Cancer and ABL Europe company providing dedicated viral vector GMP…
Read More...

Ligand Pharmaceuticals asserted that it has forayed into a worldwide OmniAb platform license agreement with Ferring Pharmaceuticals. As per the terms of the agreement, Ferring…
Read More...

Astellas Pharma confirmed acquisition of MitoBridge. Astellas shelled out $225 million to acquire 100% of the equity in Mitobridge. The acquisition sets the tone for Astellas's further…
Read More...

Surefire Medical affirmed the appointment of Mary T. Szela as its CEO, President and a member of the company's Board Of Directors. James Chomas PhD precedes Szela who served as…
Read More...

One of the leading pharmaceutical companies in the Middle East and North Africa region, Tabuk Pharmaceuticals enters into licensing and supply agreement with red otc development GmbH on…
Read More...

Celgene Corporation and Juno Therapeutics signed a definitive merger agreement in which Celgene has initiated acquisition of Juno Therapeutics. As per the terms of the agreement, …
Read More...

Amgen affirms optimistic outcomes for Phase 3b LIBERTY study evaluating the efficacy and safety of Aimovig (erenumab) 140 mg in patients with episodic migraine who had experienced two…
Read More...

Selexis SA appoints Alberto Garotti as its Chief Financial Officer. Selexis is a life sciences company focusing on revolutionizing mammalian cell line generation technology. Mr. Garotti…
Read More...

In a bid to develop contrast agents with reduced renal toxicity, Ligand Pharmaceuticals set to initiate a program to develop contrast agents with lessened renal toxicity. Enabling usage…
Read More...

Pandion Therapeutics declared the completion of a $58 million Series A financing that will be utilized to further its drug programs for autoimmune and inflammatory diseases in addition…
Read More...

U.S FDA clears OBI Pharma's investigational new drug (IND) application for a Phase 1 study of a monoclonal antibody cancer immunotherapy targeting Globo H, a glycolipid antigen…
Read More...

BioLineRx, committed to oncology and immunology declared partial results from the monotherapy portion of BL-8040's Phase 2a COMBAT study. The study reveals that BL-8040 increases…
Read More...

APRINOIA Therapeutics into  tau, alpha-synuclein, and novel targets for neurodegenerative diseases declared the completion of its US$11.1 million Series B round to finance preclinical…
Read More...

Ophthalmic Pharmaceutical Company, Aerie Pharmaceuticals that seeks to treat patients with open-angle glaucoma and other diseases of the eye declared the appointment of Nils Hauptmann…
Read More...

Developer of surgical implants for treating distal extremity pathology, Centric Medical asserted that the U.S FDA has granted 510 (k) clearance to the Cannulated Screw Internal Fixation…
Read More...

Lustgarten Foundation alleges $22 million funding in 2017 as part of its mission to invest an unprecedented $40 million by the end of 2018. In a bid to advanced pancreatic Cancer…
Read More...

Genomic and Medical research knowledge base powered by the blockchain and owned by its community, Luna DNA declared Dawn Barry as president. Barry will be held accountable for leading…
Read More...

Following the league of leading in the markets of  clinical research organizations, Optimapharm obtained Czech CRO company MKS research. Following the acquisition , Optimapharm will…
Read More...